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ABSTRACT PAGE
Posttranslational modifications by the small proteins ubiquitin and SUMO control the 
localization, activity and degradation of intracellular substrates. In recent years our 
knowledge of the crosstalk between the SUMO and ubiquitin systems has expanded 
significantly as exemplified by a novel class of enzymes called SUMO-targeted Ubiquitin 
Ligases (STUbLs). This study focuses on the Slx5/Slx8 heterodimer, a STUbL with an 
important role in genome maintenace and regulation of SUMO-conjugate levels in 
Saccharomyces cerevisiae. The Slx5/Slx8 STUbL relies on SUMO-interacting motifs 
(SIMs) in Slx5 for substrate targeting and a carboxy-terminal RING domain in Slx5 and 
Slx8 for substrate ubiquitylation. In budding yeast cells Slx5 and Slx8 reside in the nucleus, 
form distinct foci, and can associate with double-stranded DNA (dsDNA) breaks. We 
hypothesized that distinct targeting and protein interaction domains in Slx5 affect its 
binding with substrates, Slx8, and SUMO. Therefore, we constructed and analyzed 
truncations of the Slx5 protein. Our structure function analysis revealed a specific domain 
in Slx5 that is required for nuclear localization. A truncation mutant, Slx5(1-207), that lacks 
this domain fails to enter the nucleus, accumulates in the cytosol, and is enriched at the 
bud-neck of dividing yeast cells where it co-localizes with septin proteins. In a two-hybrid 
assay Slx5(1-207) failed to interact with the septins Cdc3, Cdc11, and Shs1, but interacted 
strongly with the SUMO ligase Siz1. Since Siz1 localizes to the bud-neck in a cell cycle- 
specific manner and is required for septin sumoylation we tested whether Slx5 functionally 
interacts with Siz1. First, we found that both full-length and Slx5(1-207) interact robustly 
with Slx5 in a two-hybrid assay and in co-precipitation assays. Second, deletion of SLX5 
and SLX8 result in dramatically reduced septin sumoylation in G2/M arrested cells. Third, 
a purified Siz1 protein is an in vitro ubiquitylation target of the Slx5/Slx8 STUbL. This study 
provides the first evidence that STUbLs may regulate the sumoylation of cytosolic proteins 
and functionally interact with the SUMO ligase Siz1 in vivo and in vitro.
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INTRODUCTION 
Ubiquitin and SUMO
Eukaryotic cells have implemented a intricate and highly conserved 
mechanism to modulate the function of specific proteins through the attachment 
of two small modifying proteins called ubiquitin and SUMO (Small Ubiquitin-like 
Modifier). SUMO and ubiquitin are the most prominent members of a conserved 
family of post-translational modifiers called ubiquitin-like proteins (Ubls). 
Members of the Ubl family share a three dimensional shape, the (3-GRASP fold, 
as part of their conserved structure and have key roles in the suppression of 
genomic instability and cell growth (as reviewed by Perry et al., 2008). These two 
Ubls play various roles in regulating the half-life, activity, localization and 
interactions of a plethora of proteins they are known to modify (Kerscher et al, 
2006). Proteins modified by ubiquitin and SUMO play important roles in 
processes including transcription, DNA repair, and cell cycle control to name a 
few (Hochstrasser, 2009).
Processing ubiquitin and SUMO precursors
In mammals and yeast alike, ubiquitin is expressed as a polyubiquitin fusion 
protein or as a fusion between ubiquitin and ribosomal polypeptides (as reviewed 
by Kimura and Tanaka, 2010). Processing of these ubiquitin fusion proteins by 
deubiquitinating enzymes (DUBs) produces monomeric ubiquitin capable of 
covalently modifying target proteins. Additionally, DUBs remove ubiquitin from
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substrates, thus playing a dual role in the dynamic regulation of ubiquitin 
modified proteins in the cell.
Contrary to ubiquitin, SUMO precursors are not expressed as fusion proteins, 
however, they still require processing by SUMO-specific proteases (Ulps) that 
render them capable of covalent conjugation to substrates . Three isoforms of 
SUMO exist in mammals (SUM01, 2, and 3) and only one type of SUMO exists 
in yeast (Smt3).
The conjugation of ubiquitin and SUMO to substrates
The energy dependent conjugation of ubiquitin or SUMO to a target is 
orchestrated by an enzymatic cascade involving E1 activating, E2 conjugating 
and E3 ligating enzymes, processes termed ubiquitylation or sumoylation, 
respectively (reviewed by Kerscher et al., 2006; Xie et al., 2007) (Model 1).
The Ubl enzyme cascade generally employs target specificity through the E3 
ligating enzymes, which harbor substrate binding sites (reviewed by Bergink and 
Jentsch, 2009). Interestingly, a consensus motif for covalent SUMO modification 
has been reported while a ubiquitylation motif remains to be described. SUMO is 
attached to a substrate covalently at a consensus motif on the target. The SUMO 
E2 conjugating enzyme, Ubc9, assists in the conjugation of SUMO by 
recognizing this motif( iJjKXE : i|j is a hydrophobic amino acid, and X is any 
amino acid).
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Model 1. The ubiquitin and SUMO substrates conjugation cycle. Once a Ubl 
(purple sphere) is conjugation competent, lysine side chains of a substrate 
protein (orange sphere) and a carboxy-terminus attachment motif of the Ubl form 
a covalent bond. The attachment of the Ubl imparts functional modifications to 
the substrate. SUMO and ubiquitin can be attached to substrates as monomers 
or multimers. Ubl chains formation results due to modification of specific lysines 
within the Ubls themselves. The conjugation of a Ubl to it targets occurs in a 
unidirectional nature as a result of varying relative affinities between the E1, E2 
and E3 enzymes (blue, pink and yellow spheres) (reviewed by Kerscher et al., 
2006). The Ubls can then be dynamically removed by Ubl-specific proteases 
(DUBs and Ulps).
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The consequences of ubiquitylation or sumoylation
Ubiquitylation or sumoylation in vivo usually result in different ends for a target 
protein. The downstream effects of sumoylation on a target protein can result in 
events like sequestration from a binding partner, the localization of a binding 
partner to the modified target, or conformational change in the target protein 
(reviewed by Geiss-Friedlander & Melchior, 2007 ). On the other hand, in the 
majority of cases, ubiquitylation in vivo results in proteasomal destruction of the 
target (as reviewed by Ulrich, 2005).
Several SUMO functions can be illustrated by two representative SUMO- 
substrate interactions. The yeast polymerase processing factor PCNA is 
sumoylated in vivo and this modification incurs two downstream effects. First, the 
modification acts as a signal to recruit the DNA helicase Srs2. The recruitment of 
Srs2 takes part in a pathway which allows error free DNA replication. Second, the 
SUMO modification of PCNA prevents interaction with elements of the Rad51 
mediated homologous recombination pathway, which are not desirable at sites of 
DNA synthesis. Therefore, SUMO modification of PCNA recruits one binding 
partner and deters the interaction with others (Papouli et al., 2005).
A second representative SUMO substrate is thymine DNA glycosylase (TDG). 
TDG is an enzyme that removes mismatched thymine and uracil bases. In 
performing its function TDG removes the unwanted bases and remains tightly 
bound to the DNA. The modification of TDG with SUMO causes a conformational 
change that releases the enzyme from the DNA ( Kerscher, 2007). Other SUMO 
modified substrates and results of their modification can be seen in Table 1.
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Table 1. Examples of SUMO function
Protein Description of 
Function
SUMO’s Role Reference
k B a Sumoylation blocks 
phosphorylation and 
subsequent 
ubiquitylation
Prevents degradation Reviewed by 
Ulrich, 2005
PCNA Sumoylated to recruit 
the SIM containing 
helicase Srs2
Protein interaction Papouli et al., 
2005
PML SIMs and SUMO on 
each PML protein act 
as scaffold for 
nuclear body 
formation
Nuclear body formation Reviewed by 
Seeler and 
Dejean, 2003
Smad4 Sumoylation of this 
transcription factor 
recruits the SIM 
containing 
transcriptional 
repressor, Daxx
transcriptional
repression
Chang et al., 2005
Rad52 Sumoylation of 
Rad52 negatively 
affects its
recombination activity
Attenuation of activity Sacher et al., 2006
Cdc3, Cdc11, Shs1 These septins 
become briefly 
sumoylated in M- 
phase
Function unknown Johnson et al., 
2001
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As mentioned the majority of known ubiquitin substrates are destined for 
proteasomal degradation. The 26S proteasome recognizes polyubiquitylated 
proteins and degrades them into small peptides in order to allow for proper 
protein quality control, transcriptional regulation and cell-cycle progression 
(Hochstrasser, 2009). However, ubiquitin, like SUMO, has other functions that 
can impart dynamic changes in the activity and localization of modified 
substrates. A representative substrate for ubiquitin modification, the tumor 
suppressor p53, illustrates the versatility of ubiquitin as a post-translational 
modifier. p53 can be polyubiquitylated, in which case it is destined for 
proteasomal destruction, or it can be monoubiquitylated which causes its export 
from the nucleus and sequestration from its transcriptional targets (Boyd et al., 
2000; Geyer et al., 2000).
Crosstalk between SUMO and ubiquitin
Despite the fact that thousands of targets are known to be modified by 
ubiquitin and SUMO, the details of the down stream effects of these 
modifications are often unclear, especially in the case of SUMO. Elucidation of 
these pathways becomes complicated for three main reasons. First, the transient 
and dynamic nature of Ubl modification makes it difficult to track the effects of Ubl 
modifications to their ends. Second, at any given time a very small percentage of 
a target protein is in its Ubl modified state. Third, in recent years the cross-talk 
between the SUMO and ubiquitin systems has proven to be very complex . Some 
proteins, including PCNA and p53 mentioned above, are modified by both SUMO
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and ubiquitin (reviewed by Ulrich, 2005). The relationship between SUMO and 
ubiquitin modification was originally thought to be antagonistic due to competition 
for the same lysine residues on shared substrates. However, further research 
revealed that Ubl modification cannot necessarily be understood at the level of 
an individual substrate. SUMO and ubiquitin can compete for target lysines, but 
they can also have sequential effects on a target. For example, SUMO or 
ubiquitin conjugation may at one point in the cell cycle promote transcription of a 
particular gene and at a different point suppress transcription. The overall effect 
is based on the very temporal and cumulative effects underlying a specific 
landscape of Ubl modifications in the pathway. The possibilities for SUMO and 
ubiquitin modification become blurred even further when one considers elements 
like possible branched ubiquitin chains and SUMO chains that become modified 
with ubiquitin (reviewed by Bergink and Jentsch, 2009).
A good example of the cumulative effects of SUMO and ubiquitin is the NF-kB 
pathway. NF-kB is a transcriptional activator that is sequestered in the cytosol. 
An inhibitor called kBa binds NF-kB and maintains its cytosolic localization . 
kBa is first phosphorylated by a kinase called IKK, following phosphorylation 
ubiquitylation of kBa causes it to be degraded. Degradation of kBa allows 
access of NF-kB into the nucleus. In an antagonistic role, sumoylation of kBa 
prevents it ubiquitylation and subsequent degradation, thus preventing entrance 
of NF-kB into the nucleus. Intriguingly, SUMO and ubiquitin cooperate to activate 
NF-kB through the modification of a subunit of the IKK kinase called NEMO. 
Genotoxic stress induces the SUMO modification of NEMO in the cytosol; at this
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point in time the IKK kinase is inactive. Sumoylation causes NEMO to be 
imported into the nucleus where it is first phosphorylated and then ubiquitylated. 
Addition of ubiquitin to NEMO causes it to leave the nucleus and join up with the 
other subunits of IKK. While NEMO is ubiquitylated IKK is in its active state and 
can promote the degradation of IkBo and the activation of NF-kB ( reviewed by 
Ulrich, 2005).
Non-covalent interaction with SUMO and ubiquitin
Many proteins can recognize and interact with substrates of Ubl modification 
in a non-covalent manner. Non-covalent interactors of SUMO and ubiquitin 
contain SUMO-interacting motifs (SIMs) or ubiquitin binding domains, 
respectively. In the case of ubiquitin, at least 20 different UBDs have been 
described and this number continues to grow (as reviewed by Hicke et al., 2005). 
There is no common structure that the various UBDs use to interact with 
ubiquitin; however, distinct examples have shown that structures including single 
or double helices, as well as (B-strands or loops are responsible for the ubiquitin 
interaction (as reviewed by Hicke et al., 2005). Interestingly, there is a 
commonality in the surface on ubiquitin that UBDs contact. This surface is a 
hydrophobic patch of residues in ubiquitin that is centered around Ile44.
In the case of SUMO only one canonical SUMO-interacting motif (SIM) has 
been characterized (Hochstrasser, 2009; Kerscher, 2007). Known SIM containing 
proteins harbor a loose consensus motif (V/l-X-V/l-V/l) that forms a hydrophobic
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extension (Song et al., 2004). This extension of the SIM embeds in a groove 
within SUMO that shares its hydrophobic properties.
Slx5/Slx8: A SUMO-targeted Ubiquitin Ligase
The Slx5/Slx8 complex is the founding member of a novel class of ubiquitin 
E3 ligases, termed STUbLs (SUMO-targeted Ubiquitin ligases). The cooperative 
crosstalk between the SUMO and ubiquitin systems has taken new directions 
with the discovery of this unique subclass of E3 ligases. The discovery of 
STUbLs has revealed a novel role for SUMO in proteolytic degradation. As a 
heterodimer with Slx8, Slx5 is believed to aid in the targeting of sumoylated 
proteins using its four bona fide SIMs. Then, Slx8 is believed to carry out the 
sequential ubiquitin-ligase function of the complex through the activity of its RING 
domain, a hallmark of ubiquitin E3 ligases. STUbLs have been suggested to play 
roles in telomere maintenance, transcriptional regulation, DNA repair and protein 
quality control among others (reviewed by Heideker et al., 2009; Wang and 
Prelich, 2009).
The role of STUbls in genome stability
Slx5 and Slx8 were originally isolated from a synthetic lethal screen with the 
DNA helicase Sgs1 which is required for genome stability (Mullen et al., 2001). 
Since their identification in this initial screen, multiple lines of evidence suggest 
that Slx5/Slx8 is required for genome integrity and proper DNA damage response 
by controlling cellular levels of sumoylated proteins (Zhang et al., 2006; Uzunova
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et al., 2007; Xie et al., 2007). First, mutations in SLX5 and SLX8 cause elevated 
rates of gross chromosomal rearrangements (GCRs) and spontaneous DNA 
damage. Secondly, Slx5 and Slx8 play a critical role in limiting the significantly 
greater levels of high-molecular weight SUMO-conjugates found in both single 
and double knockout strains for the heterodimer. Additionally, Slx5 forms distinct 
foci in the nuclei of live yeast cells, co-localizes with DNA repair foci, and 
interacts with double stranded DNA breaks ( Nagai et al., 2008, Cook et al., 
2009 ). These foci are dependent upon the presence of SUMO, the ability of the 
cells to synthesize poly-SUMO chains, and the presence of SIMs within the Slx5 
protein (Cook et al., 2009). Slx5 may bind directly to chromatin by interacting with 
sumoylated target proteins at sites of DNA repair. In fact, Slx5 has been shown to 
co-localize with the DNA damage repair protein Rad52, a known SUMO target, 
within sites of DNA repair, and Rad52 was identified as the first in vitro substrate 
of the Slx5/Slx8 STUbL (Xie et al., 2007).
In vivo substrates of Slx5/Slx8 and RNF4
In vivo substrates of the Slx5/Slx8 complex include the transcriptional 
regulator Mot1, which regulates the activities of TATA-binding protein, and the 
transcription factors MATal and MATa2, which regulate information encoded at 
the mating type locus in budding yeast (Wang and Prelich, 2009; Xie et al., 2010; 
Nixon et al., 2010).
STUbLs, and specifically the Slx5/Slx8 complex, are conserved from yeast to 
humans. The human ortholog of Slx5/Slx8, RNF4, has been shown to
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ubiquitylate and degrade the sumoylated oncogenic fusion protein PML-RARa in 
acute promyelocytic leukaemia (APL) (Lallemand-Breitenbach et al., 2008). In 
patients with APL, treatment with arsenic trioxide induces sumoylation of wild- 
type PML and the oncogenic fusion protein. In turn, RNF4 targets these 
sumoylated PML proteins and tags them with ubiquitin. The ubiquitylated proteins 
are recognized and degraded by the proteasome. Interestingly, and distinct from 
the Slx5/Slx8 complex, substrate ubiquitylation by RNF4 requires 
homodimerization of the conserved E3 RING domain ( Liew et al., 2011). Insights 
into Slx5/Slx8 may shed light on RNF4 and its substrates.
Slx5/Slx8 and the SUMO pathway
Several lines of evidence suggest that the Slx5/Slx8 complex is connected to 
the SUMO pathway. The first evidence came when Slx5 was identified in a two- 
hybrid screen as having a strong interaction with Smt3, yeast SUMO ( Uetz et al., 
2000; Hannich et al., 2005). Further supporting this notion, Wang and colleagues 
identified Slx5 and Slx8 as having synthetic lethality with several components of 
the sumoylation machinery (Wang et al., 2006). Slx5 and Slx8 mutant strains 
were synthetically lethal or synthetically sick with the majority of SUMO pathway 
components in budding yeast including: the SUMO E1 (AOS1/UBA2), the SUMO 
E2 (UBC9), the SUMO E3 (SIZ2) and SUMO (SMT3). Curiously, there was no 
effect on slx5A and slx8A strains when the SUMO E3 Siz1 was mutated. This is 
intriguing because Siz1, along with Siz2, is responsible for 90% of sumoylation in 
budding yeast.
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Additionally, Slx5 was identified as a high-copy suppressor of a ulplts mutant 
(Xie et al., 2007); at the nonpermissive temperature, the SUMO protease Ulp1 is 
nonfunctional and cannot cleave SUMO from substrates nor process the SUMO 
precursor into its conjugation competent form. The fact that Slx5 can rescue this 
mutant provided further evidence for a link between Slx5/Slx8 and the 
sumoylation pathway.
Siz1 and Siz2: SUMO E3 ligases
As mentioned above, the majority of sumoylation in budding yeast is executed 
by two of three E3 ligases, Siz1 and Siz2. Siz1 and Siz2 belong to the Siz/PIAS 
(protein inhibitor of activated STAT) family of SUMO E3 ligases which are found 
in all eukaryotes (Reindle et al., 2006). Siz/PIAS family E3s contain an SP-RING 
domain which is similar to the ubiquitin ligase RING domain (Hochstrasser, 
2001). In addition to the SP-RING domain Siz/PIAS proteins contain a SAP 
domain responsible for DNA binding (Reindle et al., 2006). Within yeast cells 
there are several distinct types of sumoylated conjugates. The first of these is the 
pool in which Siz1 is required for substrate sumoylation, including the nuclear 
protein PCNA and the cytosolic septin proteins. The second pool requires Siz2 
for modification, which includes several unidentified proteins. The third pool 
requires both Siz1 and Siz2; there are many substrates in this group, most of 
which have not yet been identified but includes Top2, topoisomerase II. Lastly, 
the Net1 protein can be modified by any of the three known E3 ligases in budding 
yeast (Reindle et al., 2006).
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While Siz2 is thought to play primarily a nuclear role in sumoylation, Siz1 is 
dynamically shuttled between the nucleus and the cytoplasm. Siz1 localizes to 
the bud-neck just before mitosis and is primarily responsible for the cytosolic 
sumoylation of the septins Cdc3, Cdc11, and Shs1/Sep7 in yeast cells (Johnson 
and Gupta, 2001; Takahashi et al., 2005). The karyopherin Kap95 is responsible 
for importing Siz1, while Kap142/Msn5 exports Siz1 to the cytoplasm.
Septin sumoylation
The septins are one of the most interesting groups of sumoylated proteins in 
the cell. The septin proteins belong to a family of GTPases and, despite being 
the most sumoylated proteins in mitosis, the implications of septin sumoylation 
are yet to be described. The modification of yeast septins occurs prior to 
anaphase and is terminated by the Ulp1 SUMO protease at cytokenesis 
(Johnson and Blobel, 1999; Takahashi et al., 1999). In yeast the septins form a 
ring composed of 10nm filaments which has two primary functions: 1) The 
septins act as a scaffold for other protein-protein interactions at the bud-neck and 
2) they prevent the diffusion of membrane proteins between the mother cell and 
the daughter bud. Septins have been implicated in roles including; bud-site 
selection, cell polarity, cytokenesis, and microtubule organization (Johnson and 
Blobel, 1999; as reviewed by Spiliotis, 2010). Septins are absent in plants; 
however, they are highly conserved from yeast to humans (reviewed by Spiliotis, 
2010; reviewed by Takahashi et al., 2008). While yeast only express seven 
septins, mammals express 30 septin protein isoforms produced by 14 genes
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(Spiliotis, 2010). Defects in septin proteins have been implicated in several 
pathological conditions including tumorigenesis and Parkinson disease (as 
reviewed by Barral and Kinoshita, 2008).
This study: a role for Slx5/Slx8 in cytosolic sumoylation
The Slx5/Slx8 heterodimer constitutes a SUMO-targeted Ubiquitin Ligase 
(STUbL) with an important role in regulating the levels of sumoylated proteins. 
This STUbL relies on SUMO-interacting motifs (SIMs) in Slx5 for substrate 
targeting and a carboxy-terminal RING domain in Slx5 and Slx8 for substrate 
ubiquitylation. In budding yeast cells Slx5 and Slx8 reside in the nucleus, form 
distinct foci, and can associate with double-stranded DNA (dsDNA) breaks. It is 
also known that Slx5 and Slx8 have strong genetic interactions with the 
enzymes of the SUMO conjugation pathway and several in vivo targets of the 
STUbL have been revealed. However, little is known about the precise functional 
interactions of Slx5/Slx8 in the nuclei of living cells. The goal of this research was 
to better characterize STUbL activity through a structure-function assay of 
individual domains in the targeting subunit of the complex, Slx5. Here we present 
our analysis of I) the domains involved in the subnuclear localization of Slx5; II) 
the domains within Slx5 required for interaction with its known binding partners; 
and III) a potential role for the Slx5/Slx8 STUbL in the regulation of protein 
sumoylation through the interaction with and putative regulation of an important 
SUMO pathway enzyme, Siz1.
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MATERIALS AND METHODS 
Yeast strains. Media and Plasmids.
Yeast strains and plasmids used in this study are listed in the Appendix: 
Supplementary Table 1. Yeast media preparation and manipulation of yeast cells 
was performed as previously published (Guthrie and Fink, 1991). Yeast strains 
were grown at 30°C unless otherwise noted. DNA fragments containing full- 
length and truncations of Slx5 under control of its endogenous promotor were 
amplified from yeast genomic DNA and placed in-frame with a carboxy-terminal 
GFP tag in the CEN/LEU2 plasmid pAA3. All construct were sequence verified. 
For two-hybrid constructs ORFs or truncations of the indicated genes were PCR- 
amplified and homologously recombined into gapped pOAD and pOBD2 vectors 
(Yeast Resource Center, WA). All constructs were sequence verified. For the in 
vitro ubiquitylation and pulldown assays MBP-Slx5 and MBP-Slx8 were over­
expressed from the pMALc-HT vector (A gift from Sean Prigge, JHSOM) in 
bacterial cells containing a pRIL plasmid. Siz1 was over-expressed from a 
plasmid attained from AddGene -  pT-77-SIZ1 A440-His (Takahashi et al., 2005) 
and the His6-Ubc4 plasmid was attained from (Boston Biochem). For the in vivo 
pulldown assays GST-Slx5 was purchased from the Open Biosystems yeast 
GST-tagged collection. The pRS424 Gal-Siz1 His/Flag plasmid was a gift from 
Erica Johnson and the 9MYC-Siz1 strain was a gift from Helle Ulrich.
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Yeast Two-Hybrid Assays
The indicated Gal4-activation-domain (AD) fusion constructs and Gal4- 
binding-domain fusion constructs were transformed into the AH109 (Clontech) 
reporter strain. Interactions were scored on dropout media lacking adenine. Cells 
were either struck onto the media or spotted and analyzed after three days of 
growth.
Pulldown Assays. Affinity Purification, and Protein Extracts
Induction of protein over-expression with IPTG in bacteria -  One colony of 
BL21(DE3) or *R cells expressing the recombinant protein to be purified was 
inoculated in 4 ml_ of LB broth containing the appropriate antibiotic and grown up 
overnight by rotating at 37°C. This 4 mL culture was transferred to a flask 
containing 200 mL SOC and grown up at 37°C to ODeoo 0.3-0.4. A 1 mL sample 
of this uninduced culture was collected and centrifuged. After discarding the 
supernatant, the cell pellet was resuspended in 60 pL of 1x LDS Sample Buffer 
(Invitrogen) containing BME (40 pL/1 mL sample buffer). This sample was boiled 
in a 110°C heat block for three minutes and then frozen in liquid nitrogen. This 
was done a total of three times.
After adding 80 pL of 1 M IPTG to the remaining 203 mL of bacterial culture, 
these cells were transferred to a 30°C shaker, where they were induced for 3.5 -  
5 hours. Another 1 mL sample was collected as described above. To analyze 
protein induction, whole-cell protein extracts from uninduced and induced cell 
cultures were compared by running 10 pL of each 1 mL collection on a pre-cast
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NuPAGE Novex 4-12% Bis-Tris mini-gel (Invitrogen) for 55 minutes at 200 V in 
MOPS Buffer (Invitrogen). These gels were rinsed in distilled water, stained in 
either GelCode Blue (Pierce) or SimplyBlue Safe Stain (Invitrogen) for one hour, 
and destained in distilled water for another hour. Gels were placed on wet 
Whatman paper, covered with plastic wrap, and placed in a gel dryer for 
approximately 45 minutes at 80°C. The remainder of the cell culture was 
centrifuged at 4°C for 15 minutes at 5,000 RPM. After discarding the supernatant, 
cell pellets were kept on ice and gently resuspended by pipetting in 4 mL of 1x 
Halt Protease Inhibitor Cocktail (PI) (Thermo), diluted in 1x PBS. These 4 mL 
cultures were then spun down into screw-cap tubes and frozen in liquid nitrogen.
Recombinant protein purification from bacteria -  Frozen cell pellets of IPTG- 
induced BL21(DE3) or *R cells were resuspended in 800 pL 1x Halt Protease 
Inhibitor Cocktail by pipetting. 1x PBS was then added to 2 mL. Cells were 
sonicated three times using a Branson sonifier. Sonicated cells were then 
centrifuged at 4 °C for 8 minutes at approximately 15,000 RPM. Protein extracts 
were added to a 15 mL conical and diluted in 4 mL 1x PBS. Affinity columns 
(Pierce) were assembled per the manufacturer’s instructions. His6-tagged 
proteins (Ubc4 and Siz1A440) were purified on Talon beads (Clontech), and 
MBP-tagged proteins (Slx5 and Slx8) were purified on amylose resin (New 
England Biolabs). His6 proteins were eluted with elution buffer (His6: USB), and 
MBP-tagged proteins were eluted with 100 mM maltose. Glycerol was added to
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15%. Elutions were then analyzed by gel staining as described previously. 
Proteins were frozen in liquid nitrogen and stored at -80°C.
In vitro pulldown assay - MBP-Slx5, MBP-Slx8, and T7-Siz1 A440 were over­
expressed in BL21 (DE3) or *R cells by IPTG induction as described above. Fifty 
ODs of cells over-expressing either MBP-Slx5 or MBP-Slx8 were each combined 
with 50 ODs of cells over-expressing T7-Siz1A440. Fifty ODs of cells over­
expressing T7-Siz1 A440 were also collected. Whole-cell protein extracts were 
then isolated and passed through a column containing amylose resin as 
described above (Recombinant protein purification). Proteins bound to the 
amylose resin were eluted with 1x LDS Sample Buffer (Invitrogen) and analyzed 
by Western blot as described below.
In vivo yeast pulldown assays - For the GST-Slx5 pulldown of FLAG-Siz1 50 
ml yeast cultures were grown overnight in the appropriate selective media 
containing 2% raffinose at 30°C. 25 ml of the overnight raffinose culture was 
diluted into 150 ml of selective media containing 2% raffinose and 2% galactose 
for induction of the plasmids containing GST-Slx5 and FLAG-Siz1. The 150 ml 
culture was grown overnight at 30°C. 50 ml of the induced culture were harvested 
by centrifugation (5,000 rpm, 10 min., 4°C). The cell pellet was washed in 1 ml 
cold PBS and transfered to a new 2 ml micro-tube. The pellet was centrifuged 
again as above and resuspended in 1 ml cold PBS containing protease inhibitor 
(Halt Protease Inhibitor Single-Use Cocktail, EDTA-free. Thermo Scientific). Cells
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were lysed with an Omni Bead-ruptor 24 (Omni Inc.) for 2 pulses, 20s/pulse. The 
lysate was cleared by centrifugation (15, 0000 rpm, 8 min., 4°C). 750 /j \ of the 
supernatant was transfered to a new tube and 250 /yl of 1x PBS+ 1X Protease 
Inhibitor (Halt Protease Inhibitor Single-Use Cocktail, EDTA-free. Thermo 
Scientific) was added. The supernatant was cleared again as above. 2X sample 
buffer was added to a whole cell sample (Invitrogen NUPAGE Sample Buffer) 
and the sample was boiled (3 min. 110°C). The cleared lysate was added to 60 fj\ 
of PBS-washed glutathione agarose and nutated (1 h, 4°C). The beads were 
washed 4 times with 1mL 1X PBS and samples were eluted using 75 /7l of 1X 
sample buffer. The samples were boiled at 110°C for 1 min. 10 /j \ of the whole 
sample and 25 fj\ of the elutions were seperated on a Bis/Tris protein gel and 
analyzed by Western blot as described below.
For the MYC-Siz1 pulldown of Slx5(1-310)-GFP 5 ml cultures in the 
appropriate selective media containing 2% dextrose were grown overnight at 
30°C. The 5 ml cultures were diluted to OD6oo= .3 and grown at 30°C until the 
cultures were logarithmically growing. Nocodazole was added to 15 fjg/ml and 
the cells were grown at 25°C for 3 hr to arrest the cells at G2/M of the cell cycle. 
50 OD’s of each sample were harvested by centrifugation (5,000 rpm, 10 min., 
4°C). The pellets were washed with 1 ml cold 1X PBS and transfered to a new 
tube. The pellets were centrifuged again as above and resuspended in lysis 
buffer (1X PBS, 5mM EDTA, 0.5% Triton X-100, 2X Protease Inhibitor (Halt 
Protease Inhibitor Single-Use Cocktail, EDTA-free. Thermo Scientific), and 25mM 
NEM.). The samples were pulsed twice, 20s/pulse, on the Omni Bead-ruptor 24
19
(Omni Inc.). The lysates were cleared by centrifugation (15,000 rpm, 8 min., 4°C). 
750 p\ of the supernatant was transfered to a new tube and 250 p\ lysis buffer 
was added. The samples were cleared again as above and 20 p\ whole-cell 
samples were saved. 780 p\ of the cleared samples were used for the pulldown 
assay according to the instructions for the ProFoundTM c-Myc Tag IP/Co-IP Kit 
(Thermo Scientific). 50 //I of 2X non-reducing sample buffer (provided in the kit) 
was used to elute the beads. 20 p\ of the elute sample and 15 p\ of the whole-cell 
samples were analyzed by Western blot as described below.
TCA yeast protein analysis of Cdc3-YFP - Cells were grown overnight in the 
appropriate selective media containing 2% dextrose. The following day the 
cultures were diluted into the same media to OD600= .3. Cells were incubated at 
30°C until the cultures reached logorithmic growth. Nocodazole was added to the 
cultures to 15 //g/ml and the cultures were incubated at 30°C for 2.5 hr. For the 
Smt3-FLAG shift assay, 5 OD’s worth of each sample were harvested. In the 
case of the cycloheximide-chase assay the cultures were treated with 
cycloheximide (1mg per sample) and cells were harvested at the time points 
indicated in Figure 5. Each sample was about 2.5 OD’s worth of cells. The 
harvested cells were resuspended in 20% TCA and tranfered to a new 
microcentrifuge tube. The samples were spun down again and resuspended in 
400 p\ of 20%TCA. 200/71 of glass beads (Sigma G8772-500g) were added and 
the samples were shaken at 4°C for 4 min. The supernatant was transfered to a 
new tube and centrifuged. 800 p\ of 2% TCA was added to the pellets. The
20
samples were centrifuged again and the supernatant was removed. The samples 
were resuspended in 200 >l/I of TCA-sample buffer (15% glycerol, 80mM Tris 
base, 3.5% SDS, Bromophenol Blue, and BME [40 /vl/ml]). The samples were 
boiled at 110°C for 3 min., and analyzed by Western blot as described below.
In vitro Ubiquitylation Reactions. Recombinant Proteins and Anti-Bodies
In vitro ubiquitylation assay -  Sizing and quantitation of enzymes and 
substrates used in our in vitro ubiquitylation assays were performed with a 
Protein 230 kit on the Agilent 2100 Bioanalyzer according to the manufacturer’s 
instructions. 10x ubiquitylation buffer, E1 enzyme (Uba1), ATP, and 20x ubiquitin 
were provided in a commercial ubiquitylation kit (Enzo). Ubiquitylation buffer, IPP 
(100 U/ml), DTT (50 pM), E1 (Uba1), E2 (Ubc4), and E3 enzyme (Slx5-Slx8) 
were combined with purified substrate protein (T7-Siz1 A440) and ubiquitin. 
Reactions totaled 27 pL and were incubated in a 30°C heat block for three hours. 
Reactions were stopped by adding an equal volume of SUTEB sample buffer 
(0.01% bromophenol blue, 10 mM EDTA, 1% SDS, 50 mM Tris at pH 6.8, 8 M 
Urea) containing DTT (5 pL of 1 M DTT/1 mL SUTEB sample buffer). Protein 
products were boiled in a 65°C heat block for ten minutes, analyzed by Western 
blot as described below, frozen in liquid nitrogen, and stored at -80°C.
Western blot -  Proteins were separated on a pre-cast NuPAGE Novex 4-12% 
Bis-Tris gel for 55 minutes at 200 V in 1x MOPS buffer. Proteins were then 
transferred to a polyvinylidene difluorine (PVDF) membrane (Millipore) by semi­
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dry transfer in semi-dry transfer buffer (192 mM glycine, 250 mM Tris Acetate at 
pH 8.8, 20% methanol) for 30 minutes at 19 V. The blot was blocked in TBS (150 
mM NaCI, 50 mM Tris-HCI at pH 7.4) containing 4% milk for an hour and then in 
4% milk containing primary antibody overnight. a-Smt3R11B6 (Hochstrasser Lab, 
Yale), a-GST (Abeam), a-avidin-HRP (Pierce), a-T7 (Novagen), a-SUM02 
(Michael J. Matunis, JHSOM), and a-MBP (New England Biolabs) primary 
antibodies were used, all at a concentration of 1:10,000. a-GFP JL-8 (Clontech) 
was used at 1:4000. After three, five-minute washes in large volumes of TBS 
containing TWEEN20 (1 mLTWEEN20/1 LTBS), blots were incubated in a-rabbit 
HRP (Abeam) or a-mouse HRP (GE) for 90 minutes and then washed again in 
large volumes of TBST three times for five minutes each. Chemiluminescent 
substrate (Millipore) was added to the blot, which was then wrapped in Saran 
wrap and exposed to film.
Fluorescent Microscopy
Unless otherwise noted, cells we grown in rich media, arrested at G2/M using 
nocodazole (15jLyg/ml/3h/30°C), washed in ddH20 and harvested by 
centrifugation. Images of live cells were collected using a Zeiss Axioskop fitted 
with a Retiga SRV camera (Q-imaging), i-Vision software (BioVision 
Technologies), and a Uniblitz shutter assembly (Rochester, NY). Pertinent filter 
sets for the above applications include CZ909 (GFP), XF114-2 (CFP), and 
XF104-2 (YFP) (Chroma Technology Group). Images were normalized relative to 
one another using the batch convert function of i-Vision software before
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quantification and pseudo-colored and adjusted using Adobe Photoshop software 
(Adobe Systems Inc.)
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RESULTS
Targeting of Slx5 depends on a nuclear-localization domain and SIMs
Slx5 is the targeting subunit of the heterodimeric Slx5/Slx8 STUbL complex in 
budding yeast (Xie et al., 2007; Ununova et al.,2007). The Slx5 protein contains 
at least four SIMs (amino acids 24-158) and a carboxy-terminal RING domains 
(amino acids 490-620) (Figure 1A) (Mullen et al., 2001, Uzunova et al., 2007, Xie 
et al., 2007, Cook et al., 2009, Xie et al., 2010). We previously reported that SIMs 
in Slx5 are required for the formation of nuclear foci while the RING domain is 
required for activity of the Slx5/Slx8 STUbL (Cook et al., 2009, Xie et al., 2007).
Considering the important role of STUBLs in DNA repair and the 
prevention of gross chromosomal rearrangements, we asked if particular 
domains in Slx5 are required for nuclear localization. Therefore, we determined 
the sub-cellular localization of six carboxy-terminal Slx5 truncations (C1-C6) 
(Figure 1B). These Slx5 truncations differed by about 100 amino-acids in length, 
with one exception, Slx5 construct C6 was 50 amino-acids (aa) in length and 
contained only SIM1 of Slx5 (Figure 1A). We reasoned that these truncations 
would allow us to observe where particular fragments of Slx5 localized in the cell 
and we would be able to determine the domain responsible for nuclear 
localization.
All GFP-tagged Slx5 truncations and the full-length Slx5-GFP control (Cook et 
al., 2009), were expressed under control of the native Slx5 promotor. 
Representative images of cells expressing GFP-tagged Slx5 truncations were 
recorded at early log-phase (Figure 1B). Image analysis of our carboxy-terminal
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Slx5-GFP truncation revealed that the absence of the Slx5 RING domain (aa 
490-620) does not affect nuclear localization and the formation of nuclear foci. 
Interestingly, a Slx5-GFP truncation consisting only of the amino-terminal half of 
Slx5 (C3: 1-310), still showed a strong nuclear signal. This nuclear localization 
was abruptly altered in a slightly shorter Slx5-GFP truncation (C4: Slx5- 
GFP(1-207)). Slx5-GFP(1-207) appeared to reside both in the cytoplasm and in 
the nucleus. It is unlikely that the Slx5-GFP(1-207) fusion protein simply leaked 
from the nucleus because this GFP-tagged Slx5 truncation is larger (~57kDa) 
than the defined molecular weight for passive nuclear diffusion. As expected, 
constructs that were even smaller than Slx5-GFP(1-207), C5(1-104) and 
C6(1-50), also failed to be enriched in the nucleus. Therefore, the domain 
encompassing amino acid 207-310, may serve as a crucial nuclear localization 
and/or retention domain of Slx5.
We further investigated the functional relevance of the Slx5(207-310) domain. 
Fusion of Slx5(207-310) to GFP revealed that this domain, when expressed in 
wildtype yeast cells, is necessary and sufficient for nuclear localization. 
Slx5(207-310)-GFP shows a diffuse nuclear enrichment with some residual 
cytosolic staining (Figure 1B). We also deleted amino acids 207-310 from full- 
length Slx5-GFP. This construct, Slx5(A207-310), failed to enter the nucleus and 
aggregated with a perinuclear distribution pattern (data not shown). In summary, 
our data suggests that Slx5 contains a distinct domain required for nuclear 
localization.
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Figure 1. Identification of a Nuclear Localization Domain in Slx5. A) Depicted 
are six carboxy-terminal deletions (C1-C6) of Slx5. The length of each truncation 
construct is indicated by the scale above with full-length Slx5 being 620 amino- 
acids in length. Also indicated are SIMs and the RING domain of the full length 
(WT) Slx5 protein. B) Localization of each Slx5 truncation (C1-C6) (yellow arrow 
indicates bud-neck localization), the full-length Slx5 protein (WT), and the nuclear 
localization domain fragment (red arrow), amino acids 207-310, are shown.
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A truncation of Slx5 is enriched at the bud-neck of dividing cells.
Careful analysis of the carboxy-terminal truncations of Slx5 (Figure 1B) 
revealed that Slx5(C4: 1-207) mislocalized not only to the cytoplasm but also 
exhibited a strong staining of the bud-neck, reminiscent of the septin ring (Figure 
1B). Septins, including Cdc3, Cdc10, Cdc11, Cdc12 and Shs1/Sep7, form a ring­
like 10-nanometer filament structure at the junction between mother and 
daughter cell of yeast (Johnson and Blobel, 1999). These proteins play an 
important role in mitosis and cytokinesis and are involved in processes including 
microtubule capture, chitin deposition, and septum formation. Additionally, 
septins are the most highly sumoylated protein at G2/M of the cell cycle (Kusch 
et al., 2002).
In order to test if Slx5(1-207) co-localized with individual septins we 
chromosomally-tagged CDC3 with the gene encoding the yellow fluorescent 
protein (YFP). This CDC3-YFP strain was then transformed with a plasmid 
carrying SLX5(1-207) fused to the gene encoding the cyan fluorescent protein 
(CFP). Live imaging of G2/M arrested cells revealed that both Cdc3-YFP and 
Slx5(1-207)-CFP fusion proteins were expressed and co-localized to septin rings 
in the majority (-80%) of large budded cells (Figure 2A). G2/M arrested cells 
contain only one septin ring and consistent with this observation Cdc3 and Slx5 
staining was limited to this structure. In logarithmically growing cells co­
localization of Slx5(1-207) and Cdc3-YFP to one or two septin rings was 
observed (-20%). However, septin-localization of Slx5(1-207) was limited to 
large-budded cells in mitosis.
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Figure 2. SLX5(1-207) localizes to the septin ring in a SIM dependent and 
SUMO chain independent manner. A) Cells expressing Cdc3-YFP were 
transformed with SLX5(1-207)-CFP, then arrested with nocodazole and benomyl 
for 150 minutes at 25°C before microscopy. The majority of cells displayed co­
localization of SLX5(1-207)-CFP with the septin ring. B) The septin ring 
localization (arrows) of Slx5(1-207) depends on SIM1 and 2 but not SUMO 
chains.
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Since Slx5 interacts strongly with SUMO and SUMO chains (Xie et al., 2007) 
we reasoned that the mislocalization of Slx5-(1-207) to septins may also depend 
on SUMO. Several septins (Cdc3, Cdc11, and Shs1) are highly sumoylated in 
the G2/M phase of the cell cycle and may provide binding sites for the cytosolic 
Slx5 truncation. Therefore, we examined the ability of Slx5-(1-207) with a SIMA/B 
mutations (25-AAA-27 and 93-ATAA-96) to localize to septins. We previously 
showed that both SIM1 and 2 play an important role in the formation of Slx5 
nuclear foci and SUMO binding (Xie et al., 2007, Cook 2009). The Slx5-(1-207) 
SIMA/B mutant (and a control plasmid with intact SIMs) were transformed into a 
wildtype strain and arrested cells were examined. Notably, enrichment of Slx5- 
(1-207) SIMA/B to septins was greatly reduced but not eliminated (Figure 2B). 
We made a similar observation when Slx5-(1-207) was expressed in a strain that 
is unable to form polySUMO chains (smt3-R11,15,19) (Bylebyl et al., 2003). Slx5- 
(1-207) septin mislocalization was greatly reduced but not eliminated in smt3- 
R11,15,19 cells (Figure 2B).
In summary, these data suggest that the bud-neck mislocalization of the 
Slx5(1-207) truncation depends on cell cycle-specific septin sumoylation and that 
SIMs in Slx5 are necessary and sufficient for targeting of sumoylated proteins.
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Figure 3. A) Slx5 uses distinct domains to interact with Slx5, Slx8, yeast SUMO (Smt3), and 
Siz1. Left: Depicted are six carboxy-terminal deletions (C1-C6) and six amino-terminal deletions 
(N1-N6) of Slx5. The length of each truncation constructs is indicated by the scale above with 
full-length Slx5 being 620 amino-acids in length. Also indicated are SIMs and the RING domain 
of the full length (WT) Slx5 protein. Bottom right: Duplicate spots of yeast cell colony patches 
indicate two-hybrid interactions of Slx5 with full length Slx5, Slx8, Smt3 (yeast SUMO), and Siz1 
Top right: Interactions of Slx5, Slx8, SMT3, and Siz1 with individual Slx5 truncations (amino- 
terminal (N): N1-N6 and carboxy-terminal (C): C1-C6) correspond to the Slx5 truncations 
displayed on the left. B) Summary of domains identified in Slx5. Rendering of full length Slx5. 
Indicated are the location of SIMs, RING domain, NLS, yeast SUMO & Siz1 interacting domains, 
and the regions required for Slx5 and Slx8 interaction (black bars). The length of each domain 
and feature is indicated by the scale above (amino acid 1-620) with full-length Slx5.
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The STUbL subunit Slx5 has three distinct and separate protein interaction 
domains for the interaction with Six8, Six5, and SUMO.
The results obtained in our localization studies (Figure 1B) raised the 
possibility that individual domains of Slx5 may be employed for functional 
association with different types of interacting proteins. For example, sumoylated 
substrates, other STUbL subunits, or nuclear transport factors may associate 
with a particular domain within Slx5.
To test this hypothesis, we initially focused on the interaction of Slx5 with two 
known interactors, SUMO and Slx8 (Xie et al., 2007; Li et al., 2007). Specifically, 
we delineated the interaction domains of Slx5 using a collection of six amino- 
terminal (N1-N6) and six carboxy-terminal Slx5 bait truncations (C1-C6) (Figure 
3A, Left). Full-length or truncated Slx5 bait constructs (Gal4-BD fusion) were co­
transformed with the appropriate prey constructs (Gal4-AD fusion of Slx8 or 
SUMO) into a two-hybrid reporter strain (AH109). Bait/Prey interactions were 
scored as growth of double-transformants on growth media lacking adenine 
(Figure 3A, Right). Our data confirmed that full-length Slx5 interacts with SUMO 
and Slx8 (Figure 3A, Bottom Right). Furthermore, we unexpectedly found that 
full-length Slx5 can also interact with other Slx5 proteins, raising the possibility 
that this STUbL subunit, at least sometimes, may exist as a homodimer.
Analysis of the Slx5 bait truncations reveals that at least one SIM (SIM1) is 
required for interaction with yeast SUMO (see Figure 3: C6 with SUMO). In 
contrast, the interaction of Slx5 bait with other Slx5 prey proteins was 
independent of SIM1,2,3 and 4 and dependent on the domain between amino
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acid 207 and 310 (see Figure 3A: N4 and C3 with SLX5). Interestingly, Slx5 
(207-310) was the same domain required for nuclear localization of Slx5 (Fig 1B, 
Red Arrow). One possible explanation of this finding is that homodimerization is 
required for nuclear import or nuclear retention of Slx5. Another possible role 
might be that homodimerization of Slx5 may also prevent the premature 
association of this STUbL subunit with sumoylated proteins in the cytosol.
The interaction of Slx5 with Slx8 was more complex. One Slx5 truncation 
(C1), retaining only two cysteine residues (Cys494 and Cys497) of the RING 
domain, showed a reproducible though weaker interaction with Slx8. 
Surprisingly, none of the Slx5 amino-terminal deletions (N1-6) scored positive in 
our interaction assay with Slx8. This suggests that at least 50 residues of the 
amino-terminus, including SIM 1, but not the entire RING domain of Slx5 is 
required for interaction with Slx8.
To further investigate how Slx5 interacts with Slx8 we employed a full-length 
Slx5 bait construct lacking both SIM1 and SIM2 (sim-A/B Slx5) (Xie et al., 2007). 
Full-length Slx8 prey and sim-A/B Slx5 bait were co-transformed into the two- 
hybrid assay strain. As a control both constructs were also tested against SMT3 
and SLX5 constructs. In accordance with the above data, the sim-A/B Slx5 
mutant interacted strongly with Slx5, failed to interact with Smt3, and was greatly 
reduced in its interaction with Slx8 (Supplementary Figure 1A). Therefore, both 
SIMs 1 and 2 and the RING domain of Slx5 may be important for the interaction 
with Slx8. In summary, our two-hybrid fine-structure mapping defines three
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distinct Slx5 domains required for interaction with yeast SUMO (aa 1-207), Slx5 
(aa 207-310), and Slx8 (aa 1-50 and 490-620) (Figure 3B).
The STUbL subunit Slx5 forms a complex with the SUMO ligase Siz1
Because Slx5(1-207) localized to septins in a SUMO-dependent manner, we 
decided to test its interaction with potential sumoylated substrate proteins at the 
bud-neck. Despite its enrichment at the septin ring, Slx5(1-207) failed to interact 
with the septins Cdc3 and Cdc11 (data not shown). However, to our surprise, 
Slx5 interacted in a two-hybrid assay with a known septin-interacting protein, the 
SUMO E3 ligase Siz1 (Figure 2, Bottom Right). Siz1 resides in the nucleus but 
becomes enriched on the septin ring during the G2/M phase of the cell cycle to 
sumoylate septin proteins.
We decided to investigate which domains of Slx5 were required for the 
interaction with Siz1. Using our panel of Slx5 baits we found that the interaction 
of Siz1 requires at least one SIM (SIM1) for interaction with Slx5 (Figure 2B). 
The observed interaction closely mirrors the pattern we observed for interaction 
between Slx5 and SUMO. One possible reason for this finding is that the 
interaction of Slx5 with Siz1 may depend on SUMO and possibly sumoylation of 
Siz1. Indeed, when we tested the interaction of Siz1 with the Slx5 SIM A/B 
mutant, the interaction was no longer observed (Supplementary Figure 1B.)
To confirm our finding of the Slx5*Siz1 interaction we tested if both proteins 
could interact in vivo. Briefly, we constructed a yeast strain in which both GST 
epitope-tagged Slx5 and FLAG epitope-tagged Siz1 were expressed under
33
control of the strong inducible Gal promotor (Johnson and Gupta, 2001). From 
lysates of this strain, GST-tagged Slx5 was affinity purified and co-purifying Siz1 
was detected after immunoblotting with anti-FLAG antibodies (Figure 4B). 
Additionally, we analyzed a yeast strain which expressed both Slx5(1-207)-GFP 
plasmid at centromeric levels and chromosomally integrated Myc-tagged Siz1 
(Parker et al., 2008). From lysates of this strain, Myc-tagged Siz1 was affinity 
purified and co-purifying Slx5(1-207)-GFP was detected after immuno-blotting 
with an anti GFP antibodies (Figure 4A). In summary, we conclude that the 
SUMO ligase Siz1 can form a complex with the STUbL targeting subunit Slx5 in 
yeast cell.
Since the amounts of Siz1 that co-purified with Slx5 from yeast cell extracts 
were limited we also purified both proteins and tested their interaction in vitro. 
Specifically, we probed the ability of recombinant maltose-binding protein (MBP) 
fusions of Slx5 and Slx8 to interact with T7-epitope-tagged Siz1(A440). 
Siz1(A440) lacks the carboxy-terminal 439 amino acids but retains its SUMO 
ligase activity (Takahashi, 2005). Specifically, we tested the ability of Siz1(A440) 
to copurify with Slx5 and Slx8 bound to amylose/agarose beads. In this assay 
Siz1(A440) was specifically eluted with purified Slx5 and Slx8 (Figure 4C). 
Importantly, in the absence of Slx5 and Slx8, Siz1(A440) failed to bind to 
amylose/agarose beads. It was noted that the Siz1(A440) construct was not 
sumoylated in this assay, yet our data suggest that Siz1 may be able to interact 
with both subunits of the Slx5/Slx8 STUbL.
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Figure 4. The STUbL subunit Slx5 forms a complex with the SUMO ligase 
Siz1. A) Slx5 and Siz1 interact in in vivo pulldown assays. Whole-cell 
extracts of yeast cells expressing both Slx5(1-207)-GFP at CEN plasmid levels 
and chromosomally integrated Myc-tagged Siz1 (Parker et al., 2008) were 
prepared. From lysates of this strain, Myc-tagged Siz1 was affinity purified and 
co-purifying Slx5(1-207)-GFP was detected after immuno-blotting with an anti 
GFP antibody. B) Whole-cell extracts from yeast expressing Flag-tagged Siz1 
and GST-tagged Slx5 were passed though a column containing glutothione resin. 
The elute was washed and run on a 4%-12% Bis-tris gel with the WCE. The gel 
was analyzed by Western Blotting with anti-GST and anti- FLAG antibodies. C) 
Slx5 and Slx8 interact with Siz1 in an in vitro pulldown assay. Whole-cell 
extracts from bacterial cell cultures containing overexpressed MBP-Slx5 and 
Siz1A440; MBP-Slx8 and Siz1A440; and Siz1A440 were passed through a 
column containing amylose resin. Inputs and eluates were run on a 4%-12% Bis- 
Tris gels for either staining with SimplyBlue SafeStain or immunoblotting with an 
anti-T7 antibody. Figure 4C by Brooke Matson.
SixS modulates the Siz1-mediated sumoylation o f septins.
Our finding that Slx5 and Siz1 can form a complex in yeast cells led us to 
investigate how these proteins functionally interact with each other in the cell. 
Since Siz1 sumoylates septins at the G2/M phase of the cell cycle we sought to 
determine the effect of Slx5 on this process. Therefore, we examined the in vivo 
sumoylation of the septin Cdc3 in an SLX5 deletion strain (slx5A). For our 
experiments we used wildtype or slx5A cells expressing the septin Cdc3 fused to 
the yellow fluorescent protein (CDC3-YFP). These cells were either arrested in 
G2/M. CDC3-YFP was detected in protein extracts of arrested cells after western 
blotting. In logarithmically growing cells Cdc3-YFP was detected as a single 
band (data not shown). After G2/M arrest, however, Cdc3-YFP showed several 
clearly visible sumoylated adducts in wildtype cells (Figure 5). We confirmed the 
identity of these bands as sumoylated Cdc3 by over-expression of FLAG-tagged 
SUMO (Figure 5B). Unexpectedly, the sumoylation of Cdc3 in six5A cells, but not
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wildtype cells, was greatly reduced during G2/M arrest. This finding suggests
that the ability of Siz1 to sumoylate septins was altered in the SLX5 mutant.
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Figure 5. The absence of Slx5 leads to decreased sumoylation of septin 
proteins. A) Shown here are the results of a cycloheximide-chase assay of yeast 
cells expressing the YFP-tagged septin protein Cdc3 in WT and s/x5A strains. 
Yeast cell samples were harvested at the time points indicated after the addition 
of cycloheximide. Protein extracts were prepared using TCA and analyzed by 
Western blot (WB) with anti-GFP antibody. B) Expression of FLAG-tagged Smt3 
reveals a shift in the high-molecular weight modification of Cdc3, thus indicating 
the modification is SUMO. Western blots were probed with anti-PGK antibody as 
a control to demonstrate equal protein loading.
37
Several other mutants effect the sumoylation of septins including those 
lacking SIZ1, MSN1, a transport factor implicated in Siz1 export from the 
nucleus, and SLX8. Cdc3 sumoylation after G2/M arrest was dramatically 
reduced in the sizIA, msn5A and slx8A strains (EUROSCARF, Mata collection). 
The dramatic reduction in Cdc3 sumoylation in slx8A cells is consistent with a 
role for Slx5 in Siz1-mediated Cdc3 sumoylation (Figure 6). These analyses 
revealed that absence of the Slx5/Slx8 STUbL may affect either the nuclear 
export of Siz1 or its ability to sumoylate Cdc3.
Cdc3-YFP (Smt3)'
Cdc3-YFP
WB: a-GFP
Figure 6. Cdc3 sumoylation is reduced in slx5A, slx8A s iz IA  and msn5A 
strains. Protein extracts were prepared using TCA from yeast cells expressing 
the YFP-tagged septin protein Cdc3 in WT and mutant strains. The proteins were 
analyzed by Western blot (WB) with anti-GFP antibody.
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Siz1 is an in vitro ubiqitylation substrate of Slx5/Slx8
The evidence presented above suggests that Siz1 forms a complex with Slx5. 
Therefore, we tested Siz1 as a candidate substrate for the Slx5/Slx8 STUbL. For 
our in vitro ubiquitylation assays we purified the Siz1A440 truncation, shown 
above to interact with Slx5 and Slx8. Recombinant Siz1A440 was found to be 
ubiquitylated in a Slx5/Slx8 dependent fashion (Figure 7). Addition of an amino- 
terminal SUMO moiety to Siz1A440, forming SUMO-Siz1 A440, did not 
dramatically stimulate the ubiquitylation of this fusion protein. It has been shown 
that SUMO enhances the ubiquitylation of STUbL targets. However, at least in 
vitro, SUMO modification does not appear to be an absolute requirement for 
specific Slx5/Slx8 mediated ubiquitylation (Xie et al., 2010). Another interesting 
observation is that Siz1 is robustly ubiquitylated by Slx5/Slx8, but only with 2 or 3 
ubiquitins. Therefore, Siz1 A440 is either modified with short ubiquitin chains or 
becomes mono-ubiquitylation at multiple lysines. The monoubiquitylation of other 
proteins has been implicated in intracellular trafficking including nuclear export. 
Therefore, ubiquitylation of Siz1 by Slx5/Slx8 may not be a signal for proteasome 
mediated degradation.
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Figure 7. The Slx5/Slx8 STUbL complex ubiquitylates the SUMO-ligating 
enzyme Siz1 in an in vitro ubiquitylation assay. In vitro ubiquitylation 
reactions were analyzed by Western blot and probed with anti-T7 antibody to 
detect the T7-tagged Siz1A440 truncation. The high molecular weight smear in 
the ALL lane indicates ubiquitylation of Siz1. Figure 7 by Brooke Matson.
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Absence of Slx5 reduces the localization of Siz1 to the bud-neck.
Sumoylation of the septin Cdc3 during mitosis requires the Msn1-mediated 
nuclear export of Siz1 (see above and Makhnevych et al., 2007). Since deletions 
of MSN1, SLX5, and SLX8 share similar Cdc3 sumoylation defects we 
hypothesized that Slx5 and Slx8 may also modulate the nuclear export of Siz1. 
Therefore, we observed the enrichment of Siz1-GFP at the bud-neck of cells 
arrested in mitosis. Briefly, wildtype and slx5A cells were arrested with 
nocodazole and images of Siz1-GFP accumulation at the bud-neck were 
recorded using a fluorescent microcope. As expected, Siz1-GFP in wildtype cells 
showed a distinct bud-neck staining pattern after nocodazole arrest (Figure 8). 
The maximum pixel intensity of the Siz1-GFP at the bud-neck was measured for 
wildtype and slx5A cells using i-Vision software and a two-way ANOVA revealed 
that the enrichment of Siz1-GFP at the bud neck was significantly reduced in 
slx5A cells (see Figure 8 and Makhenavych et al., 2007). The lack of Siz1-GFP 
accumulation at the bud-neck was not caused by a delayed G2/M growth arrest, 
as all cells analyzed displayed a large-budded arrest phenotype with a single 
nucleus at the bud neck. These data suggest that, at least in part, reduced levels 
of bud-neck associated Siz1 may be responsible for the observed Cdc3 
sumoylation defect in slx5A cells.
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Figure 8. Reduced Siz1 localization to the bud-neck in slx5A strains. A)
Illustrated here are representative images of the WT and slx5A strains expressing 
Siz1-GFP. Logorithmically growing cells (25°C) were arrested with Nocodozole at 
G2/M (25°C) prior to microscopy. The strains were generated by a cross between 
a SLX5::KAN strain and a strain chromosomally tagged with Siz1-GFP (open 
biosystems). Diploids were sporulated then dissected and three tetrads were 
analyzed. B) The maximum pixel intensity at the bud-neck of the arrested cells 
were normalized relative to one another (see methods), measured with iVision 
software and the average maximum pixel intensity of the cell populations were 
plotted for comparison. A two-way ANOVA was run for all of the tetrad data and 
indicated the difference in WT and slx5A strains is significant with a P-value of 
less than .0001 and an F-value of 223.21. The standard error of the data was 
4.22, represented by the error bars in each column. The sample size for each 
strain of tetrad 1 was n=68, tetrad 2 n=50, tetrad 3 n=50.
The Siz1-Slx5 interaction is conserved
In order to test if the interaction between Slx5 and Siz1 was conserved from 
yeast to humans full-length RNF4 (human Slx5 ortholog) was cloned into the 
yeast two-hybrid bait construct (Gal4-BD fusion) and was co-transformed with a 
PIAS1 (human Siz1 ortholog) prey construct (Gal4-AD fusion of Slx8 or SUMO) 
into a two-hybrid reporter strain (AH109). Intriguingly, the proteins interacted and 
grew on media lacking adenine, suggesting that the interaction is conserved 
(Figure 9).
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Figure 9. The Siz1-Slx5 interaction is conserved. Two-hybrid analysis 
revealed that Slx5 and a RING mutant of its ortholog, RNF4, interact with PIAS1. 
These interactions may indicate that the crosstalk of ubiquitin and SUMO ligases 
may be conserved from yeast to humans. Spotting on media lacking tryptophan 
and leucine indicated that the yeast strains contained both the Bait (BD) and 
Prey (AD) plasmids. Growth on media lacking adenine indicated a protein 
interaction. YOK1221 is a yeast strain used as a positive control. White dashes 
indicate Bait/Prey combinations that were not tested.
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DISCUSSION
Our structure function analysis of Slx5 has led to several new insights into the 
nuclear localization, pertinent domains, and activity of the Slx5/Slx8 STUbL 
complex.
Analysis of GFP and two-hybrid truncation panels suggest that a nuclear 
localization or nuclear retention domain resides between amino acids 207 and 
310 of Slx5. The same region of the protein, amino acids 207-310, is responsible 
for Slx5*Slx5 two-hybrid interaction, implicating a putative role for dimerization in 
the nuclear-cytosolic shuttling of Slx5.
New interaction domains were also characterized within Slx5 for interaction 
with Slx8 and the SUMO E3 ligase Siz1. The Slx5*Siz1 interaction has not been 
previously reported. The conserved nature of this interaction is demonstrated by 
the two-hybrid interaction of RNF4 and PIAS1, the orthologs of Slx5 and Siz1, 
respectively.
Subsequently, we show that Siz1 not only forms a complex with Slx5, but that 
it is also an in vitro target for ubquitylation by the Slx5/Slx8 STUbL. Curiously, in 
the absence of Slx5 there is decreased sumoylation of the bud-neck septin 
proteins at G2/M of the cell cycle, and an intriguing decrease in the level of Siz1 
(responsible for sumoylation of the septins) at the bud-neck during G2/M.
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What are the protein interaction domains of Six5?
The present study reveals three novel protein interaction domains in Slx5 
termed 1) a SUMO/substrate interaction domain, 2) an Slx8 binding domain and 
3) a nuclear localization/homodimerization domain.
Identification of the SU MO/substrate interaction domain of Slx5 is based on 
the interactions of our two-hybrid panel constructs with SUMO and Siz1. 
Interaction of Slx5 with SUMO was dependent on SIM1 alone, SIM3 and 4 in 
combination, or SIM2, 3 and 4 in combination. Interestingly, the interaction of 
Slx5 with Siz1 closely mirrors the interaction with SUMO, suggesting that Siz1 
may be a STUbL substrate. The only difference was that the Slx5*Siz1 interaction 
could not take place with the presence of SIM1 alone but required SIM1 and 2 in 
combination. Furthermore, when a construct of Slx5 missing SIM1 and 2 (sim-A/ 
B Slx5) was tested with SUMO and Siz1 the interactions were abolished. We 
concluded the region of Slx5 from amino acid 1-207 constitutes a SUMO/ 
substrate interaction domain.
Based upon these data it can be suggested that the interaction is SIM 
dependent. It has been suggested that Slx5 depends on the composite and 
redundant function of SIM1-4 for interaction with SUMO in vivo, in accordance 
with our data (Xie et al., 2010). Curiously, the known degradation of the MATa2 
repressor by the Slx5/Slx8 STUbL is a SUMO independent process. However, 
the degradation of MATa2 by Slx5/Slx8 is dependent on SIM1-4. The activities 
between Slx5 and MATa2 prompt two important questions about the interaction 
between Slx5 and Siz1. First, it seems that the interaction requires SIMs in Slx5
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but it is yet to be determined whether sumoylation of Siz1 is required. Siz1 is 
autosumoylated in vivo, yet any self-regulation by this modification has not been 
elucidated (Zhou et al., 2004)). The second question is whether or not Siz1, like 
MATa2, may contain a SUMO like domain that is recognized by the Slx5/Slx8 
STUbL(Xie et al., 2010).
The second domain characterized by this study is the Slx8 binding domain of 
Slx5. Only one Slx5 C-terminal truncation, Slx5(1-517), retaining two cysteine 
residues (Cys494 and Cys497) of the RING domain, showed a reproducible but 
weaker interaction with Slx8. None of the Slx5 amino-terminal truncations 
showed interaction with Slx8. Surprisingly, the one feature present in the 
Slx5(1-517) truncation that was absent from the opposite N-terminal truncation, 
Slx5(50-620), was SIM1. This suggests that at least 50 residues of the amino- 
terminus, including SIM 1, but not the entire RING domain of Slx5 is required for 
interaction with Slx8. The RING domain of Slx5, containing a protein dimerization 
domain, is necessary for suppression of synthetic lethality with the DNA helicase 
Sgs1 ( Mullen and Brill, 2008). Also, the RING domains of both Slx5 and Slx8 are 
required for cellular DNA damage resistance ( Xie et al., 2007). While it is known 
that the Slx8 RING domain confers ubiquitin ligase activity little is known about 
the activity of the Slx5 RING domain. It has been shown that the RING domain of 
Slx5 enhances the activity of the Slx8 ubiquitylation. Due to this enhanced 
activity it has been suggested that the Slx5 RING domain may act to stabilize the 
Slx8 RING domain in an active confirmation ( Xie et al., 2007). Since SIM1 is 
required for Slx5*Slx8 interaction and given that Slx8 can also bind SUMO in vitro
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(Mullen and Brill, 2008), it is tempting to speculate that SUMO recognition by 
both Slx5 and Slx8, along with the RING domain, may play a role in the 
heterodimer association and orientation. Importantly, the human ortholog of the 
Slx5/Slx8 complex, RNF4, requires RING domain dimerization for ubiquitylation 
of targets and the protein contains SIMs.
Finally, a nuclear localization/homodimerization domain was identified in this 
study. The domain of Slx5 from amino acid 207-310 was required for both the 
nuclear localization of Slx5 and the Slx5*Slx5 two-hybird interaction. The domain 
207-310 was involved in nuclear localization and Slx5 constructs lacking this 
domain formed cytosolic aggregates in the cell. One possible explanation of this 
finding is that homodimerization is required for nuclear import or nuclear retention 
of Slx5. Several examples of proteins that require dimerization for nuclear import 
exist (Fryrear et al., 2009, Hayes et al., 2009). It is tempting to speculate that 
homodimerization of Slx5 may also prevent the premature association of this 
STUbL subunit with sumoylated proteins in the cytosol. Currently, it is unknown 
how Slx5 and Slx8 enter the nucleus. Further investigation will determine if there 
is a dynamic regulation of Slx5 and Slx8 between the nucleus and cytosol.
Does Slx5/Slx8 have a role in the cytosol?
Several other nuclear members of the SUMO pathway are dynamically 
exported into the cytosol in a cell cycle specific manner. These SUMO pathway 
components include the SUMO protease Ulp1 and the SUMO E3 ligase Siz1 
(Makhnevych et al., 2007). As mentioned above, Ulp1 and Siz1 regulate the
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sumoylation state of the bud-neck septin proteins during G2/M and cytokinesis. 
A role for Slx5/Slx8 outside of the nucleus is not an unprecedented concept. 
Unpublished data in the Kerscher lab suggest that cells lacking the nucleoporin 
Nup170 exhibit diffuse nuclear and cytosolic staining of wild-type Slx5-GFP. 
Accordingly, GFP truncations of Slx5 lacking the nuclear localization/ 
homodimerization domain from this study also show diffuse intracellular staining. 
Whether or not Slx5/Slx8 plays a role in the cytosol is yet to be determined. 
However, given the observed cytosolic localization of Slx5, the novel interaction 
with Siz1 described in this study, and the extensive evidence suggesting a role 
for Slx5 and Slx8 in the SUMO pathway (see INTRODUCTION: Slx5/Slx8 and 
the SUMO pathway), further investigation into a hypothesis suggesting a role for 
Slx5/Slx8 in regulating levels of sumoylated proteins is worthwhile. Experiments 
addressing how Slx5 may interact with nucleoporins and/or karyopherins may be 
a good platform to further our understanding.
Does Slx5 potentiate Siz1 sumoylation activity in the cytosol?
Several lines of evidence presented in this study indicate that Slx5 may 
potentiate the sumoylation activity of Siz1 in the cytosol of yeast cells. First, Slx5 
and Siz1 interact genetically in a two-hybrid assay and physically in in vivo 
pulldown assays. Second, Slx5 and Slx8 physically interact with Siz1 in vitro. 
Third, in slx5A cells arrested at G2/M there are reduced levels of Siz1 and 
SUMO-Cdc3 conjugates at the bud-neck. Lastly, Siz1 is an in vitro ubiquitylation 
target of the Slx5/Slx8 STUbL. Based on these data we hypothesize that the
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SUMO E3 ligase Siz1 may be a ubiquitylation substrate of the Slx5/Slx8 STUbL 
and that Slx5/Slx8 may regulate the cytosolic sumoylation activity of Siz1.
It has been previously reported that Siz1 is auto-sumoylated in vivo, however 
the downstream effects of this modification are unknown (Zhou et al., 2004). It 
has also been reported that the overexpression of Siz1 leads to a counter­
intuitive decrease in the level of sumoylated septins (Takahashi et al., 2001). In 
order to extrapolate upon our hypothesis that Siz1 is a substrate of the Slx5/Slx8 
STUbL, with the previous literature in mind, we propose two potential models to 
describe the mechanism resulting in reduced levels of sumoylated-Cdc3 and 
Siz1 at the bud-neck in slx5A cells during G2/M.
In the first model, we propose that the ubiquitylation of Siz1 by the Slx5/Slx8 
STUbL could lead to its nuclear export (Figure 10). Other cases have been 
described in which ubquitylation leads to export from the nucleus (as detailed 
above in the Introduction). The auto-sumoylation of Siz1 in vivo makes it an ideal 
candidate for STUbL mediated ubiquitylation. In concept, the ubiquitylation of 
Siz1 could lead to exposure of a nuclear export signal (NES), and once in the 
cytosol Siz1 would proceed to sumoylating the septin proteins. Perhaps the prior 
sumoylation of Siz1 masks the NES, retaining Siz1 in the nucleus and illustrating 
the sequential regulatory relationship between SUMO and ubiquitin modification 
described in other pathways. Deletion of SLX5 in this context would result in a 
pool of sumoylated Siz1 that is trapped in the nucleus and thus could not perform 
its function at the septin ring. Such a phenomenon is supported, in part, by the 
observed decrease in Siz1 at the bud-neck as well as decreased SUMO-Cdc3
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levels at G2/M of the cell cycle. If such a model held true, one could speculate 
that the over expression of Siz1 may overwhelm the cells ability to ubiquitylate 
the molecule causing buildup, and perhaps aggregation, of SUMO-Siz1 
conjugates in the nucleus of the cell. In turn, this buildup of SUMO-Siz1 in the 
nucleus would result in the reported decrease of septin sumoylation when Siz1 is 
over-expressed (Takahashi et al., 2008).
Figure 10. Putative model for the regulation of Siz1 by the Slx5/Slx8 STUbL.
A) In wild-type cells we propose that Slx5/Slx8 (green rectangles) may be 
targeted to sumoylated Siz1 (orange Siz1 sphere & white SUMO sphere) in the 
nucleus (Light blue sphere), leading to its ubiquitylation (dark blue sphere) (arrow 
1). The ubiquitylation of Siz1 may potentiate the export of Siz1 to the cytosol, 
lead to degradation of Siz1 by the proteasome, or both (arrow 2). B) Cells 
deficient in Slx5 can no longer regulate Siz1 appropriately, putatively resulting in 
a build-up of sumoylated Siz1 in the nucleus.
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In the second model we propose that the ubiquitylation of Siz1 by the Slx5/ 
Slx8 STUbL could lead to its proteasomal degradation (Figure 10). If Slx5/Slx8 
regulates the amount of Siz1 in the cell then it could be suggested that deletion 
of SLX5 would result in a situation similar to that presented in model one. 
Deletion of Slx5, in the context of Siz1 degradation, would result in an effective 
over-expression of Siz1. Over expression of Siz1 could lead to nuclear buildup of 
the protein, presumably the sumoylated form, and the observed decreased septin 
sumoylation. Currently there is not evidence illustrating a build-up of Siz1 in the 
nucleus.
In order to elucidate the details of the Siz1-Slx5 relationship additional key 
experiments are under way. To determine if Siz1 is being degraded by the Slx5/ 
Slx8 STUbL we are conducting a cycloheximide-chase assay, in which potein 
synthesis is halted. If Siz1 is a degradation target of Slx5/Slx8 then the level of 
Siz1, after addition of cycloheximide ,would stabilize in slx5A cells. While we 
know that Siz1 can be ubiquitylated in vitro, observation of in vivo ubiquitylation 
would complement the cycloheximide-chase assay and provide additional 
support for the data shown here. Other compelling experiments include 
examining the sumoylation or ubquitylation of Siz1 in different cellular 
compartments (i.e. nuclear vs. cytosolic) at different stages of the cell cycle.
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Summary and impact
Our structure function analysis of Slx5 has not only provided insight into the 
domains responsible for the nuclear localization and protein interaction within this 
STUbL subunit, but it has also given us a tool box for the discovery of new Slx5 
interactors. For example, one of the most remarkable observations of the current 
study is the influence of Slx5 on the SUMO E3 ligase Siz1, an observation that 
resulted directly from our studies. The interaction of RNF4 with PIAS1, the 
human orthologs of Slx5 and Siz1 respectively, emphasizes the conserved 
nature of these cellular mechanisms from yeast to humans and underscores the 
importance of our research in the budding yeast model system.
The possible regulation of a SUMO E3 ligase by a STUbL implies a novel and 
exciting crosstalk between the SUMO and ubiquitin systems. The implications of 
such regulation may have profound effects on our understanding of SUMO 
biology. The regulation of sumoylation by STUbLs would no longer be limited to 
modification and degradation of specific target proteins, but would extend to the 
regulation of enzymes responsible for SUMO modification. Control of 
sumoylation in this context would allow STUbLs to regulate sumoylated targets 
on a global scale, simultaneously regulating the processes of transcription, DNA 
repair, cell cycle control and many others. For example, the regulation of SUMO 
conjugation machinery would broaden the scope of STUbL activity in the cell, 
implicating STUbLs in the fate of countless sumoylation targets and essential 
cellular pathways.
53
An example of the new perspective this study reveals is illustrated by the 
tumor suppressor protein p53. p53 is an in vivo sumoylation target of PIAS1, the 
human ortholog of Siz1 (Kahyo et al., 2001). The sumoylation of p53 recruits the 
protein to PML bodies, and sumoylation of p53 on K386 stimulates its 
transcriptional activity. The stimulation of activity could result from an increased 
affinity of p53 for DNA or perhaps the localization and sequestration of p53 in the 
nucleus at PML bodies (Gostissa et al., 1999; Rodriguez et al., 1999). Microarray 
analysis suggests that p53 is responsible for the regulation of over 100 genes 
with important roles in regulation of the cell cycle, tumor suppression and DNA 
damage; it is for this reason that it is called the “guardian of the genome” (Allison, 
2007). Mutations in the p53 gene are linked to many types of cancer. Further, 
bioinformatic studies suggest that there are potential p53 binding sites in greater 
than 4,000 human genes (Allison, 2007). The concept that PIAS1 sumoylation of 
p53, and p53 transcriptional activity, could be indirectly regulated by STUbLs is 
groundbreaking and far-reaching.
The putative implication for p53 regulation is just one example of the effects 
that this novel crosstalk between the SUMO and ubiquitin pathways may have on 
cellular sumoylation targets. Without a doubt, in the next few years many more 
exciting details of a potential feedback loop between SUMO ligation and SUMO 
mediated degradation will emerge.
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Supplementary Figure 1. Additional two-hybrid data. A) SIM1 and 2 in Slx5 
were not essential for interaction of Slx5 with other Slx5 proteins, however, 
interaction of Slx5 with Slx8 was reduced and interaction with Smt3 was 
abolished. B) SIM1 and 2 of Slx5 were essential for the interaction with Siz1. C) 
Siz1 and Slx8 do not interact in a two-hybrid assay. Interactions were scored as 
growth on media lacking adenine.
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No Zeocin Zeocin
WT
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Supplementary Figure 2. A recent observation suggests that the STUbL Hex3/ 
Slx8 complex may interact with double stranded DNA breaks that reside in close 
proximity to nuclear pore complexes (Nagai et al., 2009). In order to test this 
hypothesis we generated a nup133A NIC96-RFP strain. In this strain deletion of 
NUP133, a nucleoporin with a role in the even distribution of nuclear pore 
complexes, results in clusters of the RFP tagged nucleoporin Nic96. 
Subsequently, the nup133A NIC96-RFP strain was transformed with a construct 
expressing Slx5-GFP. The ultimate goal of these studies is to determine if in live 
cells Slx5-GFP foci can overlap with clustered Nic96-RFP nucleoporins. Co­
localization of Slx5 and Nic96 could suggest that STUbLs may interact with 
nucleoporins and dsDNA breaks in the vicinity of nuclear pore complexes. Initial 
results suggest that Slx5 foci and NPC foci do not overlap in either wild-type or 
nup133A strains when exposed to Zeocin induced DNA damage. We aim to 
verify these data in a yeast strain that contains only a single induced dsDNA 
break. Additionally, we would like to generate three dimensional confocal images 
of Slx5 foci in yeast cell nuclei.
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Supplementary Table 1. Strains and plasmids used in this study
Name Pertinent 
Genotypes or 
Parent Strains
Plasmids Reference
YOK1220 AH109
(Clontech
Laboratories
Inc.)
(Clontech
Laboratories
Inc.)
YOK1221 AH109 & Y187 
(Clontech 
Laboratories 
Inc.)
pGBKT7-53 & pGADT7-T (Clontech 
Laboratories Inc.)
(Clontech
Laboratories
Inc.)
YOK1322 Mata his3A1 
leu2A0 
m etl 5A0 
ura3A0 
(BY4741)
Openbio
Systems
Inc.
YOK1364 CDC3-YFP/ 
HIS5 (BY4741)
SLX5(1 -207)-GFP/LEU2 
(BOK507)
This study
YOK1369 YOK1322
(BY4741)
SLX5(1 -50)-GFP/LEU2 
(BOK514)
This study
YOK1370 YOK1322
(BY4741)
SLX5(1 -104)-GFP/LEU2 
(BOK515)
This study
YOK1372 YOK1322
(BY4741)
SLX5(1 -310)-GFP/LEU2 (BOK517) This study
YOK1373 YOK1322
(BY4741)
SLX5(1 -414)-GFP/LEU2 (BOK518) This study
YOK1374 YOK1322
(BY4741)
SLX5(1 -517)-GFP/LEU2 (BOK519) This study
YOK1375 YOK1322
(BY4741)
SLX5(1 -207)-GFP/LEU2 
(BOK507)
This study
YOK1397 slx5A::G418 
CDC3-YFP/ 
HIS5 (MHY501, 
BY4741)
This study
YOK1398 slx5A::G418 
CDC3-YFP/ 
HIS5 (MHY501, 
BY4741)
This study
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Name Pertinent 
Genotypes or 
Parent Strains
Plasmids Reference
YOK1408 AH109 SLX5(1 -104)-BD/TRP; 
SLX5-AD/LEU2 (BOK289)
This study
YOK1411 AH109 SLX5(1 -207)-BD/TRP; 
SLX5-AD/LEU2 (BOK289)
This study
YOK1414 AH 109 SLX5(1-310)-BD/TRP; 
SLX5-AD/LEU2 (BOK289)
This study
YOK1417 AH 109 SLX5(1-414)-BD/TRP; 
SLX5-AD/LEU2 (BOK289)
This study
YOK1420 AH 109 SLX5(1 -517)-BD/TRP; 
SLX5-AD/LEU2 (BOK289)
This study
YOK1423 AH109 SLX5(51 -620)-BD/TRP; 
SLX5-AD/LEU2 (BOK289)
This study
YOK1425 AH 109 SLX5(105-620)-BD/TRP; 
SLX5-AD/LEU2 (BOK289)
This study
YOK1428 AH109 SLX5(208-620)-BD/TRP; 
SLX5-AD/LEU2 (BOK289)
This study
YOK1431 AH109 SLX5(311 -620)-BD/TRP; 
SLX5-AD/LEU2 (BOK289)
This study
YOK1434 AH109 SLX5(415-620)-BD/TRP; 
SLX5-AD/LEU2 (BOK289)
This study
YOK1437 AH109 SLX5(1 -104)-BD/TRP; 
SLX8-AD/LEU2 (BOK311)
This study
YOK1440 AH109 SLX5(1 -207)-BD/TRP; 
SLX8-AD/LEU2 (BOK311)
This study
YOK1443 AH109 SLX5(1-310)-BD/TRP; 
SLX8-AD/LEU2 (BOK311)
This study
YOK1446 AH 109 SLX5(1-414)-BD/TRP; 
SLX8-AD/LEU2 (BOK311)
This study
YOK1449 AH 109 SLX5(1-517)-BDfrRP; 
SLX8-AD/LEU2 (BOK311)
This study
YOK1452 AH109 SLX5(51 -620)-BD/TRP; 
SLX8-AD/LEU2 (BOK311)
This study
YOK1455 AH109 SLX5(105-620)-BD/TRP; 
SLX8-AD/LEU2 (BOK311)
This study
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YOK1458 AH109 SLX5(208-620)-BD/TRP; 
SLX8-AD/LEU2 (BOK311)
This study
YOK1461 AH 109 SLX5(311 -620)-BD/TRP; 
SLX8-AD/LEU2 (BOK311)
This study
YOK1464 AH 109 SLX5(415-620)-BD/TRP; 
SLX8-AD/LEU2 (BOK311)
This study
YOK1467 AH 109 SLX5-BD/TRP (BOK440); 
SIX5-AD/LEU2 (BOK289)
This study
YOK1470 AH109 SLX5-BD/TRP (BOK440); 
SLX8-AD/LEU2 (BOK311)
This study
YOK1491 AH 109 SLX5-BD/TRP (BOK440); 
SUM02-AD/LEU2 (BOK447)
This study
YOK1494 AH 109 SLX5-BD/TRP (BOK440); 
PIAS1-AD/LEU2 (BOK558)
This study
YOK1497 AH 109 RNF4-BD/TRP (BOK556); 
SUM02-AD/LEU2 (BOK447)
This study
YOK1500 AH109 RNF4-BD/TRP (BOK556); 
PIAS1-AD/LEU2 (BOK558)
This study
YOK1503 AH 109 RNF4-BD/TRP (BOK556); 
SUM02-AD/LEU2 (BOK447)
This study
YOK1506 AH 109 RNF4cs-BD/TRP (BOK557); 
PIAS1-AD/LEU2 (BOK558)
This study
YOK1518 AH109 SLX5-BD/TRP (BOK440); 
SMT3-AD/LEU2 (BOK571)
This study
YOK1522 YOK1322
(BY4741)
SLX5(1 -207)SIMA/B-GFP/LEU2 This study
YOK1547 AH 109 SLX5(1 -50)-BD/TRP 
SMT3-AD/LEU2 (BOK571)
This study
YOK1550 AH 109 SLX5(1 -104)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
YOK1553 AH 109 SLX5(1 -207)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
YOK1556 AH 109 SLX5(1 -310)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
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YOK1559 AH109 SLX5(1-414)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
YOK1562 AH109 SLX5(1-517)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
YOK1565 AH109 SLX5(51-620)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
YOK1568 AH 109 SLX5(311-620)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
YOK1571 AH109 SLX5(208-620)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
YOK1574 AH 109 SLX5(311-620)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
YOK1577 AH 109 SLX5(415-620)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
YOK1580 AH109 SLX5(518-620)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
YOK1583 AH109 SLX5(518-620)-BD/TRP; 
SLX8-AD/LEU2 (BOK311)
This study
YOK1586 AH109 SLX5(518-620)-BD/TRP; 
SLX5-AD/LEU2 (BOK289)
This study
YOK1589 AH109 SLX5(1 -50)-BD/TRP 
SLX8-AD/LEU2 (BOK311)
This study
YOK1592 AH109 SLX5(1 -50)-BD/TRP 
SLX5-AD/LEU2 (BOK289)
This study
YOK1595 AH 109 SLX5-BD/TRP (BOK440); 
SIZ1-AD/LEU2 (BOK582)
This study
YOK1621 AH109 SLX5(1 -50)-BD/TRP 
SIZ1-AD/LEU2 (BOK582)
This study
YOK1625 AH 109 SLX5(1 -104)-BD/TRP; 
SIZ1-AD/LEU2 (BOK582)
This study
YOK1627 AH109 SLX5(1 -207)-BD/TRP; 
SIZ1-AD/LEU2 (BOK582)
This study
YOK1630 AH109 SLX5(1 -310)-BD/TRP; 
SIZ1-AD/LEU2 (BOK582)
This study
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YOK1633 AH109 SLX5(1-414)-BD/TRP; 
SIZ1-AD/LEU2 (BOK582)
This study
YOK1636 AH 109 SLX5(1 -517)-BD/TRP; 
SIZ1-AD/LEU2 (BOK582)
This study
YOK1639 AH109 SLX5(51 -620)-BD/TRP; 
SIZ1-AD/LEU2 (BOK582)
This study
YOK1642 AH109 SLX5(311 -620)-BD/TRP; 
SIZ1-AD/LEU2 (BOK582)
This study
YOK1645 AH109 SLX5(208-620)-BD/TRP; 
SIZ1-AD/LEU2 (BOK582)
This study
YOK1648 AH 109 SLX5(311-620)-BD/TRP; 
SIZ1-AD/LEU2 (BOK582)
This study
YOK1651 AH109 SLX5(415-620)-BD/TRP; 
SIZ1-AD/LEU2 (BOK582)
This study
YOK1654 AH 109 SLX5(518-620)-BD/TRP; 
SIZ1-AD/LEU2 (BOK582)
This study
YOK1791 AH109 SLX8-AD/LEU2 (BOK311) This study
YOK1792 AH 109 SIX5-AD/LEU2 (BOK289) This study
YOK1793 AH109 SLX5(SIMAB)-BD/TRP; 
SIX5-AD/LEU2 (BOK289)
This study
YOK1794 AH 109 SLX5(SIMAB)-BD/TRP; 
SIX5-AD/LEU2 (BOK289)
This study
YOK1795 AH 109 SLX5(SIMAB)-BD/TRP; 
SIX5-AD/LEU2 (BOK289)
This study
YOK1796 AH109 SLX5(SIMAB)-BD/TRP; 
SIX8-AD/LEU2 (BOK311)
This study
YOK1797 AH 109 SLX5(SIMAB)-BD/TRP; 
SIX8-AD/LEU2 (BOK311)
This study
YOK1798 AH 109 SLX5(SIMAB)-BD/TRP; 
SIX8-AD/LEU2 (BOK311)
This study
YOK1799 AH 109 SLX5(SIMAB)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
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YOK1800 AH109 SLX5(SIMAB)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
YOK1801 AH 109 SLX5(SIMAB)-BD/TRP; 
SMT3-AD/LEU2 (BOK571)
This study
YOK1830 MHY500 SLX5(208-310)-GFP/LEU2 
(BOK637)
This study
YOK1890 slx5A::G418
SIZ1-GFP
This study
YOK1891 SIZ1-GFP This study
YOK1894 SIZ1-GFP This study
YOK1895 slx5A::G418
SIZ1-GFP
This study
YOK1898 SIZ1-GFP This study
YOK1901 slx5A::G418
SIZ1-GFP
This study
YOK2017 AH 109 SLX5-BD/TRP (BOK440); 
EMPTY-AD/LEU2 (BOK312)
This study
YOK2018 AH109 RNF4-BD/TRP (BOK556); 
EMPTY-AD/LEU2 (BOK312)
This study
YOK2019 AH109 RNF4cs-BD/TRP (BOK557); 
EMPTY-AD/LEU2 (BOK312)
This study
YOK2020 AH109 EMPTY-BD/TRP (BOK313) 
SMT3-AD/LEU2 (BOK571)
This study
YOK2021 AH 109 EMPTY-BD/TRP (BOK313) 
SIZ1-AD/LEU2 (BOK582)
This study
YOK2022 AH 109 EMPTY-BD/TRP (BOK313) 
SUM02-AD/LEU2 (BOK447)
This study
YOK2023 AH 109 EMPTY-BD/TRP (BOK313) 
PIAS1-AD/LEU2 (BOK571)
This study
YOK2037 YOK1398 SMT3gg-FLAG/LEU2 (BOK700) This study
YOK2038 YOK1397 SMT3gg-FLAG/LEU2 (BOK700) This study
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Genotypes or 
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Plasmids Reference
YOK2072 JD52 (MATa 
his3-200 
Ieu2-3,112 
Iys2-801 trp1 -63 
ura3-52)
GST-SLX5/URA (BOK629); 
SIZ1-HIS/FLAG/TRP (BOK732)
Ju et al., 
2008 & 
Openbio 
Systems 
Inc.
YOK2091 CDC3-YFP/
HIS5
YOK1322
(BY4741)
This study
YOK2092 msn5A, CDC3-
YFP/HIS5
(BY4741)
This study
YOK2093 slx8A, CDC3-
YFP/HIS5
(BY4741)
This study
YOK2094 slx5A, CDC3-
YFP/HIS5
(BY4741)
This study
YOK2095 siz1 A, CDC3-
YFP/HIS5
(BY4741)
This study
YOK2104 AH109 SIX5-AD/LEU2 (BOK289) This study
YOK2105 AH 109 SIZ1-BD/TRP (BOK599) This study
YOK2106 AH 109 SIZ1-AD/LEU2 (BOK582) This study
YOK2107 AH 109 SLX5(SIMAB)-BD/TRP (BOK627) This study
Y0K2111 AH 109 SLX5(SIMAB)-BD/TRP (BOK627); 
SIZ1-AD/LEU2 (BOK582)
This study
YOK2112 AH109 SLX5(SIMAB)-BD/TRP (BOK627); 
SIZ1-AD/LEU2 (BOK582)
This study
YOK2113 AH 109 SLX5(SIMAB)-BD/TRP (BOK627); 
SIZ1-AD/LEU2 (BOK582)
This study
YOK2196 MYC-SIZ1
(YHU2107)
SLX5(1 -310)-GFP/LEU2 (BOK517) This study
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Plasmids used for bacterial production of recombinant protein
480 His6-HsUbc4 Ubiquitin E2 -
500 BL21(DE3)s +MBP-Slx5 - This Study
501 BL21(DE3)s + MBP-Slx8 - This Study
591 T7-Siz1 A440-His pT-77 (AmpR) From AddGene Takahashi et al.,
2005
758 *Rs + T7-Siz1 A440-His BOK 591 This Study
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